publicado em 06/07/2012 às 18h02:00
   Dê o seu voto:

USP develops vaccine with the potential to stop cancer growth

Treatment with dendritic cells makes the patient's body recognize and fight cancer cells

font size

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.

A vaccine developed at the Institute of Biomedical Sciences (ICB) and the Faculty of Medicine, USP may be able to stop the advance of cancer in humans. The work is a result of cell fusion research with the patient's blood from a healthy person.

According to the author of the study, professor and immunologist doctor Jose Alexandre Barbuto, dendritic cells are components of the immune system primarily responsible for identifying and capturing foreign agents present in the human body. In a person with cancer, this cell does not recognize the tumor as something foreign to the body and, therefore, not combat. The principle of the vaccine, according to the professor, is tell the system what is bad for the body and the system should enter the fray, he explains.

Unlike what the name suggests, the vaccine is not made for that healthy people protect themselves from cancer. The name confuses many people, but the vaccine is not only preventative, it can be therapeutic also serve as an alternative treatment to a particular disease, says the researcher.

The developed material is made in single doses for each particular patient. Dendritic cells are removed from the patient's blood, which carries a tumor marker, and fused to the base shocks with other blood cells from healthy donors.

This form of treatment is used for two types of cancer: skin cancer (melanoma) and kidney cancer, usually in patients with end-stage. In most cases, the tumor has stopped growing. In terminally ill patients, the estimated life more than doubled.

With the advancement of research, the teacher hopes that soon it can be used on a larger scale and will help not only patients with end-stage, but also in the beginning of treatment to make it tolerable and less painful.

Neuroblastoma <b> </ b>

Another type of cancer that is recently being studied neuroblastoma is common in children whose development differs from the others. According to Barbuto, is a cancer that often heals itself, but there is no definitive cure. It operates, transplanted, and he can return. The vaccine is prepared similarly, but is applied immediately after the operation, leaving no time to return the tumor to develop.

Despite the promising start, Barbuto remember that although it is not possible to verify the results, since the method and the research is quite recent. You have to wait longer for us to have more reliable answers, he says.

With information <i> USP </ i>

   Palavras-chave:   USP    Dendritic cells    Melanoma    Kidney cancer    Neuroblastoma   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: USP develops vaccine with the potential to stop cancer growth
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: USP develops vaccine with the potential to stop cancer growth

Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
USP    dendritic cells    melanoma    kidney cancer    Neuroblastoma   
Leave your comment
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story:
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaú
Get the newsletter of the portal  iSaú
Recommend the portal iSaú
News from  iSaú in your blog or website.
Get news on the subject of your interest.
© 2000-2011 Todos os direitos reservados.